Dyne Therapeutics
DYN
15.50
-0.53
-3.31%
Dyne Therapeutics
US · DYN
#2540 by market cap
Listed 2020
15.50
-0.53
-3.31%
Periodic snapshot; not a real-time feed.
· 2026-11-20 19:30
Recent news
-
RBC Capital Maintains Dyne Therapeutics(DYN.US) With Buy Rating, Maintains Target Price $30Market Newswire · 2026/11/6
-
Company notice
Walter Dyn: Measures for the Management of Market Capitalization of Shandong Walter Dyn Health Co., Ltd.SZSI · 2026/8/21
-
Morgan Stanley Maintains Dyne Therapeutics(DYN.US) With Buy Rating, Maintains Target Price $36Market Newswire · 2026/11/6
-
Rating change
Stifel Maintains Dyne Therapeutics(DYN.US) With Buy Rating, Maintains Target Price $37Market Newswire · 2026/9/30
-
LifeSci Capital Maintains Dyne Therapeutics(DYN.US) With Buy Rating, Maintains Target Price $40Market Newswire · 2026/9/30
-
Company notice
Walter Dyn: Internal Review System for Information Disclosure and Responses on the Interactive Platform of Shandong Walter Dyn Health Co., Ltd.SZSI · 2026/10/30
-
Rating change
J.P. Morgan Downgrades Dyne Therapeutics(DYN.US) to Sell Rating, Announces Target Price $10Market Newswire · 2026/9/11
-
Rating change
Raymond James Maintains Dyne Therapeutics(DYN.US) With Buy Rating, Cuts Target Price to $37Market Newswire · 2026/9/24
-
Rating change
A Quick Look at Today's Ratings for Dyne Therapeutics(DYN.US), With a Forecast Between $26 to $50Market Newswire · 2026/9/9
-
Rating change
Baird Maintains Dyne Therapeutics(DYN.US) With Buy Rating, Cuts Target Price to $26Market Newswire · 2026/9/10
-
H.C. Wainwright Maintains Dyne Therapeutics(DYN.US) With Buy Rating, Cuts Target Price to $32Market Newswire · 2026/11/6
-
Rating change
Piper Sandler Maintains Dyne Therapeutics(DYN.US) With Buy Rating, Maintains Target Price $47Market Newswire · 2026/9/29
-
Rating change
Jefferies Initiates Dyne Therapeutics(DYN.US) With Buy Rating, Announces Target Price $50Market Newswire · 2026/9/8
-
Company notice
Walter Dyn: Compensation Management System for Directors and Senior Management of Shandong Walter Dyn Health Co., Ltd.SZSI · 2026/4/24
-
Raymond James Maintains Dyne Therapeutics(DYN.US) With Buy Rating, Raises Target Price to $41Market Newswire · 2026/11/12
-
Rating change
Raymond James Maintains Dyne Therapeutics(DYN.US) With Buy Rating, Maintains Target Price $40Market Newswire · 2026/8/25
-
Company notice
Walter Dyn: Summary Table of Non-Operating Fund Occupancy and Other Related Party Transactions for the First Half of 2026, Shandong Walter Dyn Health Co., Ltd.SZSI · 2026/8/21
-
Rating change
Morgan Stanley Maintains Dyne Therapeutics(DYN.US) With Buy Rating, Cuts Target Price to $36Market Newswire · 2026/9/10
-
Company notice
Walter Dyn: 2025 Annual Internal Control Audit Report of Shandong Walter Dyn Health Co., Ltd.SZSI · 2026/4/24
-
Rating change
H.C. Wainwright Maintains Dyne Therapeutics(DYN.US) With Buy Rating, Maintains Target Price $50Market Newswire · 2026/8/17
-
Rating change
Raymond James Maintains Dyne Therapeutics(DYN.US) With Buy Rating, Raises Target Price to $40Market Newswire · 2026/8/5
-
Rating change
Morgan Stanley Maintains Dyne Therapeutics(DYN.US) With Buy Rating, Cuts Target Price to $45Market Newswire · 2026/7/31
-
Rating change
A Quick Look at Today's Ratings for Dyne Therapeutics(DYN.US), With a Forecast Between $44 to $47Market Newswire · 2026/7/31
-
H.C. Wainwright Maintains Dyne Therapeutics(DYN.US) With Buy Rating, Cuts Target Price to $32Market Newswire · 2026/9/30
-
Company notice
Walter Dyn: Special Statement on Non-Operating Fund Occupancy and Other Related Party Transactions for the Year 2025 of Shandong Walter Dyn Health Co., Ltd.SZSI · 2026/4/24
Headlines are aggregated automatically and are not independently verified or edited by our team.
Quote time 2026-11-20 19:30:05 · For reference only, not investment advice and not tailored to your situation.
Dyne Therapeutics discussion 0 comments